NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Metrics to compare | ALNFL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNFLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −4.8x | −0.5x | |
PEG Ratio | - | 0.07 | 0.00 | |
Price/Book | 14.9x | 3.2x | 2.6x | |
Price / LTM Sales | 88,860.2x | 22.7x | 3.3x | |
Upside (Analyst Target) | 239.1% | 124.5% | 45.8% | |
Fair Value Upside | Unlock | −2.7% | 6.4% | Unlock |